Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.
Website: resmed.com



Growth: Good revenue growth rate 12.5%, there is slowdown compared to average historical growth rates 13.6%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -4.6%

Profitability: LTM EBITDA margin is positive, +29.3%. On average the margin is decreasing unsteadily. Gross margin is high, +55.6%. In the last quarter the company beat the estimated EPS, +5.7%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 1.0%. Free cash flow yield 1.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 36.5% higher than minimum and 38.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.6x by EV / Sales multiple , the company can be 42.6% overvalued

Insiders: For the last 3 months insiders sold company shares on $2.0 mln (-0.008% of cap.)

Key Financials (Download financials)

Ticker: RMD
Share price, USD:  (-0.2%)183.78
year average price 182.41  


year start price 225.30 2023-04-27

max close price 240.96 2023-04-28

min close price 134.65 2023-10-27

current price 183.78 2024-04-25
Common stocks: 147 132 000

Dividend Yield:  1.0%
FCF Yield LTM: 1.9%
EV / LTM EBITDA: 21.4x
EV / EBITDA annualized: 22.0x
Last revenue growth (y/y):  12.5%
Last growth of EBITDA (y/y):  0.6%
Historical revenue growth:  13.6%
Historical growth of EBITDA:  7.2%
EV / Sales: 6.3x
Margin (EBITDA LTM / Revenue): 29.3%
Fundamental value created in LTM:
Market Cap ($m): 27 040
Net Debt ($m): 1 181
EV (Enterprise Value): 28 221
Price to Book: 6.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-18Zacks Investment Research

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2024-04-01Zacks Investment Research

Here's Why Investors Should Buy ResMed (RMD) Stock Now

2024-03-31InvestorPlace

The 7 Best Stocks to Buy With Your Required Minimum Distribution (RMD)

2024-03-07Zacks Investment Research

ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40

2024-02-23Zacks Investment Research

Why Is ResMed (RMD) Down 1.7% Since Last Earnings Report?

2024-02-20Zacks Investment Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

2024-02-16Zacks Investment Research

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

2024-02-13Zacks Investment Research

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

2024-02-05Zacks Investment Research

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

2024-01-29CNBC Television

Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2024-01-25 2023-10-27 2023-08-11 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
revenue 1 163M 963M 1 122M 1 117M 1 034M 950M
costOfRevenue 516M 363M 505M 499M 454M 409M
grossProfit 647M 600M 617M 618M 580M 541M
grossProfitRatio 0.556 0.623 0.550 0.553 0.561 0.569
researchAndDevelopmentExpenses 74M 76M 78M 76M 70M 63M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 222M 223M 241M 228M 212M 194M
otherExpenses -686 000 12M 61 000 12M 10M 8M
operatingExpenses 308M 311M 331M 317M 291M 265M
costAndExpenses 823M 674M 836M 816M 745M 675M
interestIncome 0 18M 0 0 0 0
interestExpense -14M -15M -15M -15M -10M -7M
depreciationAndAmortization 53M 53M 55M 46M 62M 23M
ebitda 457M 289M 334M 347M 343M 299M
ebitdaratio 0.393 0.300 0.297 0.311 0.331 0.314
operatingIncome 275M 289M 275M 301M 280M 276M
operatingIncomeRatio 0.237 0.300 0.245 0.269 0.271 0.290
totalOtherIncomeExpensesNet -66M -17M 6M -11M -7M -14M
incomeBeforeTax 259M 272M 277M 289M 274M 262M
incomeBeforeTaxRatio 0.223 0.283 0.247 0.259 0.265 0.275
incomeTaxExpense 51M 53M 47M 57M 49M 51M
netIncome 209M 219M 230M 233M 225M 210M
netIncomeRatio 0.180 0.228 0.205 0.208 0.218 0.221
eps 1.420 1.490 1.560 1.580 1.530 1.440
epsdiluted 1.420 1.490 1.560 1.580 1.530 1.430
weightedAverageShsOut 147M 147M 147M 147M 147M 146M
weightedAverageShsOutDil 148M 147M 148M 147M 147M 147M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2024-01-25 2023-10-27 2023-08-11 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 210M 209M 228M 228M 253M 207M
shortTermInvestments 8M 12M 0 0 0 0
cashAndShortTermInvestments 210M 209M 228M 228M 253M 207M
netReceivables 730M 692M 705M 686M 672M 620M
inventory 933M 958M 998M 1 011M 989M 865M
otherCurrentAssets 180M 445M 437M 412M 147M 341M
totalCurrentAssets 2 378M 2 305M 2 368M 2 338M 2 325M 2 034M
propertyPlantEquipmentNet 705M 657M 666M 656M 651M 613M
goodwill 2 862M 2 812M 2 770M 2 784M 2 767M 1 939M
intangibleAssets 528M 563M 552M 570M 587M 338M
goodwillAndIntangibleAssets 3 390M 3 375M 3 323M 3 353M 3 354M 2 277M
longTermInvestments 160M -265M -395M 0 -346M 0
taxAssets 156M 403M 395M 96M 346M 81M
otherNonCurrentAssets 116M 265M 395M 271M 346M 173M
totalNonCurrentAssets 4 527M 4 436M 4 384M 4 376M 4 351M 3 144M
otherAssets 0 0 0 0 0 0
totalAssets 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M
accountPayables 202M 177M 151M 162M 196M 181M
shortTermDebt 34M 32M 32M 33M 32M 31M
taxPayables 47M 67M 72M 78M 58M 48M
deferredRevenue 149M 147M 138M 141M 134M 108M
otherCurrentLiabilities 379M 415M 438M 426M 370M 372M
totalCurrentLiabilities 764M 771M 759M 762M 733M 693M
longTermDebt 1 357M 1 464M 1 548M 1 691M 1 907M 900M
deferredRevenueNonCurrent 127M 121M 119M 109M 103M 98M
deferredTaxLiabilitiesNonCurrent 89M 88M 91M 113M 108M 12M
otherNonCurrentLiabilities 85M 46M 105M 107M 88M 731M
totalNonCurrentLiabilities 1 659M 1 720M 1 863M 2 020M 2 205M 1 052M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 165M 134M 139M 138M 139M 135M
totalLiabilities 2 423M 2 490M 2 622M 2 781M 2 938M 1 745M
preferredStock 0 0 0 0 0 0
commonStock 588 000 588 000 588 000 588 000 588 000 586 000
retainedEarnings 4 540M 4 402M 4 253M 4 088M 3 920M 3 760M
accumulatedOtherComprehensiveIncomeLoss -208M -320M -273M -262M -270M -406M
othertotalStockholdersEquity 150M 168M 149M 106M 88M 79M
totalStockholdersEquity 4 482M 4 250M 4 130M 3 933M 3 738M 3 433M
totalEquity 4 482M 4 250M 4 130M 3 933M 3 738M 3 433M
totalLiabilitiesAndStockholdersEquity 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M
totalInvestments 160M -265M -395M 0 -346M 0
totalDebt 1 391M 1 496M 1 580M 1 724M 1 939M 931M
netDebt 1 181M 1 287M 1 352M 1 496M 1 686M 723M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2024-01-25 2023-10-27 2023-08-11 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
netIncome 209M 219M 230M 233M 225M 210M
depreciationAndAmortization 53M 53M 55M 53M 46M 44M
deferredIncomeTax 44M -33M 7M 0 0 0
stockBasedCompensation 20M 19M 20M 18M 16M 17M
changeInWorkingCapital -44M -10M -63M -14M -153M -232M
accountsReceivables -27M 7M -18M -13M -20M -56M
inventory 50M 27M 6M -22M -86M -147M
accountsPayables -44M 0 330 000 0 0 8M
otherWorkingCapital -23M -33M -52M 20M -47M -37M
otherNonCashItems -9M 38M -11M -6M -6M 5M
netCashProvidedByOperatingActivities 273M 286M 237M 283M 129M 45M
investmentsInPropertyPlantAndEquipment -25M -41M -39M -31M -32M -32M
acquisitionsNet -8M -103M -2M -13M -992M -19M
purchasesOfInvestments -9M -5M -6M -13M -13M -7M
salesMaturitiesOfInvestments 5M 250 000 4M 16M 10M 0
otherInvestingActivites -5M 0 -4M 13M 0 0
netCashUsedForInvestingActivites -41M -149M -47M -28M -1 026M -59M
debtRepayment -130M -185M -145M -215M -15M -30M
commonStockIssued 20M 983 000 23M 983 000 22M 3M
commonStockRepurchased -50M 105M 0 0 0 0
dividendsPaid -71M -71M -65M -65M -65M -64M
otherFinancingActivites -8M -2M -2M -900 000 990M 50M
netCashUsedProvidedByFinancingActivities -239M -151M -189M -280M 933M -42M
effectOfForexChangesOnCash 8M -5M -2M -208 000 11M -11M
netChangeInCash 1M -19M -3000.000 -25M 46M -67M
cashAtEndOfPeriod 210M 209M 228M 228M 253M 207M
cashAtBeginningOfPeriod 209M 228M 228M 253M 207M 274M
operatingCashFlow 273M 286M 237M 283M 129M 45M
capitalExpenditure -25M -41M -39M -31M -32M -32M
freeCashFlow 248M 245M 199M 251M 97M 12M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-01-24 ET (fiscal 2024 q2)
2023 q3
2023-10-26 ET (fiscal 2024 q1)
2023 q2
2023-08-03 ET (fiscal 2023 q4)
2023 q1
2023-04-27 ET (fiscal 2023 q3)
2022 q4
2023-01-26 ET (fiscal 2023 q2)
2022 q3
2022-10-27 ET (fiscal 2023 q1)
2022 q2
2022-08-11 ET (fiscal 2022 q4)
2022 q1
2022-04-28 ET (fiscal 2022 q3)
2021 q4
2022-01-27 ET (fiscal 2022 q2)
2021 q3
2021-10-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-04 20:05 ET
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
2024-03-15 07:05 ET
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
2024-03-15 07:05 ET
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
2024-03-06 14:05 ET
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
2024-02-12 21:16 ET
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
2024-01-24 21:05 ET
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
2024-01-03 21:05 ET
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
2023-12-27 21:05 ET
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:05 ET
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
2023-12-11 21:05 ET
ResMed Secures Significant Victory in Patent Fight Against New York University
2023-12-07 20:34 ET
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
2023-11-09 21:05 ET
ResMed Adopts New Operating Model to Accelerate Long-term Growth
2023-11-09 21:05 ET
ResMed Adopts New Operating Model to Accelerate Long-term Growth
2023-10-26 20:05 ET
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
2023-10-05 20:05 ET
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
2023-09-05 20:05 ET
ResMed Announces Participation in Upcoming Conferences
2023-08-03 20:05 ET
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023
2023-07-06 20:05 ET
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
2023-07-05 20:05 ET
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
2023-07-05 20:05 ET
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
2023-06-08 13:00 ET
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
2023-06-08 13:00 ET
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
2023-06-05 20:05 ET
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-25 13:00 ET
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
2023-05-25 13:00 ET
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
2023-05-02 20:05 ET
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
2023-05-02 20:05 ET
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
2023-04-27 20:05 ET
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023
2023-04-06 20:05 ET
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
2023-03-30 20:05 ET
ResMed Chief Administrative Officer and Global General Counsel to Retire
2023-03-30 20:05 ET
ResMed Chief Administrative Officer and Global General Counsel to Retire
2023-03-15 20:19 ET
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
2023-03-13 11:00 ET
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
2023-03-13 11:00 ET
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
2023-03-07 14:00 ET
ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference
2023-01-26 21:05 ET
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
2023-01-26 21:05 ET
ResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair Emeritus
2023-01-26 21:05 ET
ResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair Emeritus
2023-01-12 14:00 ET
ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023
2023-01-02 21:05 ET
ResMed Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
2022-11-22 14:00 ET
ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
2022-11-22 14:00 ET
ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
2022-10-27 20:05 ET
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023
2022-10-13 20:05 ET
ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
2022-09-07 13:00 ET
ResMed Announces Participation in the Bank of America Global Healthcare Conference
2022-09-06 13:00 ET
ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference
2022-09-04 12:00 ET
Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports
2022-09-04 12:00 ET
Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports
2022-08-11 20:05 ET
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022
2022-08-02 09:00 ET
ResMed Acquires Leipzig-based mementor with Insomnia Digital Health Solution somnio
2022-07-14 20:05 ET
ResMed to Report Fourth Quarter Fiscal 2022 Earnings on August 11, 2022
2022-06-28 13:00 ET
ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care
2022-06-28 13:00 ET
ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care
2022-06-14 06:05 ET
ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions
2022-06-14 06:05 ET
ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions
2022-06-07 13:00 ET
ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference
2022-06-01 13:00 ET
ResMed Announces Participation in the 42nd Annual William Blair Growth Stock Conference
2022-05-25 13:00 ET
ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference
2022-05-25 13:00 ET
ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference
2022-05-18 20:05 ET
Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study
2022-05-18 20:05 ET
Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study
2022-05-05 20:05 ET
ResMed Announces Leadership Change
2022-05-05 20:05 ET
ResMed Announces Leadership Change
2022-04-28 20:05 ET
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022
2022-04-28 20:05 ET
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022
2022-04-27 20:05 ET
ResMed Announces Participation in the 24th Annual Macquarie Australia Conference
2022-04-27 20:05 ET
ResMed Announces Participation in the 24th Annual Macquarie Australia Conference
2022-04-07 20:05 ET
ResMed to Report Third Quarter Fiscal 2022 Earnings on April 28, 2022

SEC forms

Show financial reports only

SEC form 10
2024-01-25 00:00 ET
ResMed published news for 2023 q4
SEC form 10
2024-01-24 19:50 ET
ResMed published news for 2023 q4
SEC form 8
2024-01-24 16:06 ET
ResMed published news for 2023 q4
SEC form 8
2024-01-24 16:06 ET
ResMed reported for 2023 q4
SEC form 10
2023-10-27 00:00 ET
ResMed published news for 2023 q3
SEC form 10
2023-10-26 19:38 ET
ResMed published news for 2023 q3
SEC form 8
2023-10-26 16:05 ET
ResMed reported for 2023 q3
SEC form 10
2023-08-11 00:00 ET
ResMed published news for 2023 q2
SEC form 6
2023-08-03 16:06 ET
ResMed reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
ResMed published news for 2023 q2
SEC form 10
2023-04-28 00:00 ET
ResMed published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
ResMed published news for 2023 q1
SEC form 6
2023-03-30 16:36 ET
ResMed published news for 2022 q4
SEC form 10
2023-01-27 00:00 ET
ResMed reported for 2022 q4
SEC form 10
2023-01-26 18:09 ET
ResMed reported for 2022 q4
SEC form 6
2023-01-26 16:05 ET
ResMed published news for 2022 q4
SEC form 8
2023-01-26 00:00 ET
ResMed reported for 2022 q4
SEC form 6
2022-11-17 16:08 ET
ResMed published news for 2022 q3
SEC form 10
2022-10-28 00:00 ET
ResMed reported for 2022 q3
SEC form 10
2022-10-27 18:26 ET
ResMed reported for 2022 q3
SEC form 6
2022-10-27 16:05 ET
ResMed published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
ResMed reported for 2022 q3
SEC form 6
2022-10-05 14:02 ET
ResMed published news for 2022 q3
SEC form 10
2022-08-12 00:00 ET
ResMed reported for 2022 q2
SEC form 10
2022-08-11 21:09 ET
ResMed reported for 2022 q2
SEC form 6
2022-08-11 20:57 ET
ResMed published news for 2022 q2
SEC form 6
2022-08-11 16:07 ET
ResMed published news for 2022 q2
SEC form 8
2022-08-11 00:00 ET
ResMed reported for 2022 q2
SEC form 6
2022-07-01 13:03 ET
ResMed published news for 2022 q2
SEC form 6
2022-06-30 17:28 ET
ResMed published news for 2022 q1
SEC form 6
2022-06-14 09:07 ET
ResMed published news for 2022 q1
SEC form 6
2022-05-11 16:28 ET
ResMed published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
ResMed reported for 2022 q1
SEC form 10
2022-04-28 18:47 ET
ResMed reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
ResMed published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
ResMed reported for 2022 q1
SEC form 10
2022-01-28 00:00 ET
ResMed published news for 2021 q4
SEC form 10
2022-01-27 18:21 ET
ResMed published news for 2021 q4
SEC form 6
2022-01-27 16:06 ET
ResMed published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
ResMed published news for 2021 q4
SEC form 6
2021-11-19 14:31 ET
ResMed published news for 2021 q3
SEC form 10
2021-10-29 00:00 ET
ResMed published news for 2021 q3
SEC form 10
2021-10-28 18:28 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-28 16:07 ET
ResMed published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-07 14:03 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-06 12:08 ET
ResMed published news for 2021 q3
SEC form 6
2021-09-13 16:01 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-27 16:06 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-19 10:23 ET
ResMed published news for 2021 q2
SEC form 10
2021-08-17 00:00 ET
ResMed published news for 2021 q2
SEC form 10
2021-08-16 21:43 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-05 16:08 ET
ResMed published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
ResMed published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
ResMed published news for 2021 q1
SEC form 10
2021-04-29 19:50 ET
ResMed published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
ResMed published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
ResMed published news for 2021 q1
SEC form 6
2021-03-29 17:54 ET
ResMed published news for 2020 q4
SEC form 10
2021-01-28 17:55 ET
ResMed published news for 2020 q4
SEC form 6
2021-01-28 16:05 ET
ResMed published news for 2020 q4
SEC form 6
2020-11-20 16:05 ET
ResMed published news for 2020 q3
SEC form 6
2020-11-05 16:08 ET
ResMed published news for 2020 q3
SEC form 10
2020-10-29 19:21 ET
ResMed published news for 2020 q3
SEC form 6
2020-10-29 16:05 ET
ResMed published news for 2020 q3
SEC form 6
2020-10-06 16:12 ET
ResMed published news for 2020 q3